Research programme: siRNA diabetes therapy - Alnylam Pharmaceuticals
Latest Information Update: 16 May 2014
At a glance
- Originator Sirna Therapeutics
- Class Nucleotides; RNA
- Mechanism of Action RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus